Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients

A research study evaluating a new oncolytic virus, THEO-260, in patients with advanced ovarian cancer. The trial will investigate different doses of THEO-260 administered by the intraperitoneal route to identify a dose that is safe, well tolerated, and exhibits preliminary evidence of anti tumour activity.

Trial Details

NCT ID

NCT07211659

Phase

PHASE1

Sponsor

Theolytics Limited

Status

RECRUITING

Cancer Type

Ovarian Cancer

Interventions

THEO-260

Locations (sample)

Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

Confirmed histological diagnosis of advanced high grade serous or endometrioid cancer of the fallopian tube, primary peritoneum or ovary either on …
Platinum-resistant or refractory disease: platinum-resistance is defined as radiological progression within 6 months of last cycle of platinum trea…
Life expectancy of \> 6 months.
ECOG performance status of 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →